Create your page here
Latest News for: teva pharmaceuticals
Edit
Multiple Sclerosis Pipeline 2024: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights ...
GetNews 28 Jan 2025
Key companies developing therapies for Multiple Sclerosis are - Celgene, Actelion (now Janssen Pulmonary Hypertension), EMD Serono, Inc., Bayer, Acorda Therapeutics, Inc., Biogen, Teva Pharmaceuticals, Novartis, Sanofi, F.
Edit
Hastings Tribune
27 Jan 2025
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for
affiliate of Teva Pharmaceutical Industries .
Edit
Hastings Tribune
27 Jan 2025
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05,
affiliate of Teva Pharmaceutical Industries .
Edit
Chronic Pulmonary Infections Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight ...
GetNews 27 Jan 2025
Armata Pharmaceuticals ... Hoffmann-La Roche Ltd, Novartis AG, GlaxoSmithKline Plc, AstraZeneca Plc, Boehringer Ingelheim International Gmbh, Teva Pharmaceutical Industries Ltd, Sanofi, Mylan Pharmaceuticals, Sun Pharmaceutical, and others.
Edit
Migraine Pipeline 2024: Key Developments, Emerging Therapies, and Clinical Trials Detailed Analysis by DelveInsight | ...
GetNews 24 Jan 2025
In April 2024, Teva Pharmaceuticals has revealed promising results from a Phase III study assessing Ajovy (fremanezumab) for migraine prevention in Chinese adult patients.
Edit
Overactive Bladder Pipeline 2024: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights ...
GetNews 23 Jan 2025
... Pharma Inc., Laborie, Endo International PLC, Hisamitsu Pharma, Inc., Medtronic, Pfizer Inc, Teva Pharma, AbbVie Inc, Allergan, Macleods Pharmaceuticals Ltd, Urovant Sciences, Uro Medical, and others.
Edit
Chronic Pain Therapeutics Market Size in the 7MM is anticipated to increase by 2034 and ...
GetNews 22 Jan 2025
... Tonix Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Vertanical GmbH, and others.
Edit
ABSSSI Therapeutics Market Size in the 7MM is anticipated to increase by 2034 and according ...
GetNews 22 Jan 2025
The leading Acute Bacterial Skin and Skin Structure Infections Companies such as Melinta Therapeutics, LLC, Merck, Pfizer, Allergan, Paratek Pharmaceuticals, Cumberland Pharmaceuticals, Teva Pharmaceuticals, and others.
Edit
Musculoskeletal Pain Therapeutics Market Size in the 7MM is expected to grow by 2034 and ...
GetNews 21 Jan 2025
The leading Musculoskeletal Pain Companies such as Eli Lilly and Company, Sun Pharma Global FZE, Flexion Therapeutics, Taisho Pharmaceutical, Anika Therapeutics, Mesoblast, Regeneron Pharmaceutical, ...
Edit
Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama®
Pharmiweb 20 Jan 2025
In mid-January 2025, Formycon and Teva Pharmaceuticals International GmbH (Teva) signed a licensing agreement for the semi-exclusive commercialization of FYB203 across major parts of Europe and Israel.
Edit
Chronic Lymphocytic Leukemia Pipeline 2024: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight ...
GetNews 20 Jan 2025
Hoffmann-La Roche Ltd, AstraZeneca, Secura Bio, Inc, Novartis AG, AbbVie, Inc., Gilead Sciences, Inc., BeiGene, Inc., Sanofi (Genzyme Corporation), Ziopharm Oncology Inc, Ono pharmaceuticals Co Ltd, Teva Pharmaceutical Industries, and others.
Edit
The next 15 drugs chosen for Medicare negotiation
The Hill 17 Jan 2025
The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts before the inauguration of President-elect Trump ... For treating ... Forest Pharmaceuticals ... Teva Pharmaceuticals ... Salix Pharmaceuticals.
Edit
Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
NBC Bay Area 17 Jan 2025
In separate statements, Bristol Myers Squibb, Teva Pharmaceuticals and Boehringer Ingelheim argued that the price talks could hurt patient access and future innovation in the industry.
Edit
Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., ...
GetNews 16 Jan 2025
Key companies developing therapies for Gastroparesis are - Bayer AG, Cipla Limited, Evoke Pharma, Pfizer Inc., Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Salix Pharmaceuticals, Inc., The Takeda Pharmaceutical, Teva Pharmaceutical, and others.
Edit
Restrictive Cardiomyopathy Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Array Biopharma, ...
GetNews 16 Jan 2025
Inc., Pfizer Inc., Capricor Therapeutics, MyoKardia, Janssen Products, GlaxSoSmithKline, Teva Pharmaceuticals, Cipla, Sun Pharmaceuticals, and others ... Cipla, Sun Pharmaceuticals, and others.
- 1
- 2
- Next page »